This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Logan, A. G. Articles by Haynes, R. B. Search for Related Content PubMed PubMed Citation Articles by Logan, A. G. Articles by Haynes, R. B.

Hypertension, Vol 3, 211-218, Copyright © 1981 by American Heart Association

ARTICLES

Cost-effectiveness of a worksite hypertension treatment program

AG Logan, BJ Milne, C Achber, WP Campbell and RB Haynes

The cost-effectiveness of treating hypertension at the patient's place of work was compared in a randomized controlled trial with care delivered in a community. The average total cost per patient for worksite care in this 12-month study was not significantly different from that for regular care ($242.86 +/- 6.94 vs $211.34 +/- 18.66, mean +/- SEM). The worksite health system cost was significantly more expensive ($197.36 +/- 4.99 vs $129.33 +/- 13.34, p less than 0.001) but the patient cost was significantly less ($45.40 +/- 3.23 vs $82.00 +/- 6.20, p less than 0.01). The mean reduction in diastolic blood pressure (BP) at the year-end assessment was significantly greater in the worksite group (12.1 +/- 0.6 vs 6.5 +/- 0.6 mm Hg, p less than 0.001). The incremental cost-effectiveness ratio of $5.63 per mm Hg for worksite care was less than the base cost-effectiveness ratio of $32.51 per mm Hg for regular care, indicating that the worksite program was substantially more cost-effective. Our findings support health policies that favor allocating resources to work-based hypertension treatment programs for the target group identified in this study.

This article has been cited by other articles:

				Y. Bravo Vergel and M. Sculpher Quality-adjusted life years Practical Neurology, June 1, 2008; 8(3): 175 - 182. [Abstract] [Full Text] [PDF]

				R. A Elliott, N. Barber, and R. Horne Cost-Effectiveness of Adherence-Enhancing Interventions: A Quality Assessment of the Evidence Ann. Pharmacother., March 1, 2005; 39(3): 508 - 515. [Abstract] [Full Text] [PDF]

				H. P. McDonald, A. X. Garg, and R. B. Haynes Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review JAMA, December 11, 2002; 288(22): 2868 - 2879. [Abstract] [Full Text] [PDF]

				R. B. Haynes, H. P. McDonald, and A. X. Garg Helping Patients Follow Prescribed Treatment: Clinical Applications JAMA, December 11, 2002; 288(22): 2880 - 2883. [Abstract] [Full Text] [PDF]

				M. Johannesson The Impact of Age on the Cost - Effectiveness of Hypertension Treatment: An Analysis of Randomized Drug Trials Med Decis Making, August 1, 1994; 14(3): 236 - 244. [Abstract] [PDF]

				M. F. Drummond, J. Heyse, J. Cook, and A. McGuire Selection of End Points in Economic Evaluations of Coronary-heart-disease Interventions Med Decis Making, August 1, 1993; 13(3): 184 - 190. [Abstract] [PDF]

				D. W. Belcher Implementing Preventive Services: Success and Failure in an Outpatient Trial Arch Intern Med, December 1, 1990; 150(12): 2533 - 2541. [Abstract] [PDF]